Get Premium

Get Premium

Dominate Financial Markets with Stock Target Advisor Premium Features

Discover
Discover

Explore new stock opportunities and market trends for better investment decisions.
- Analyst Ratings & Stock Picks
- Top Picks By AI
- Latest Analyst Ratings
- Analyst Directory
- Worst Stocks
- Sector Ratings & Performance
- Smart Filters
- Best Penny Stocks
- Best Dividend Stocks
- Best Crypto Stocks
- Best Performing Stocks
- Worst Performing Stocks
- Highest Income ETFs
Research
Research

Access in-depth stock analysis and expert evaluations to guide your investments
- Automatic Selection
- Stocks/ETF Screener
- Query Builder
- Analyst Screener
- Automated Research Reports
- Best Stocks Filters
- Thematic Stock Screens
- Sector Stock Screens
Learn
Learn

Utilize our extensive educational resources designed to enhance your investing knowledge and skills
- Market News & Insights
- Stock Target Advisor Insights
- Tutorials
- Market News
- Stock Calendars
- Earnings Calendar
- IPO Calendar
- Splits Calendar
Watchlists & Portfolios
Watchlists & Portfolios

Easily manage, track, and optimize your stock selections for maximum returns
Engage
Engage

Connect with the investing community and access free widgets for better stock insights
Pricing

Limited Time Offer: Save Up to 70% on all Packages

Leverage our advanced stock screeners, a custom dashboard, and market-leading tools to maximize your returns. Claim Now

Dianthus Therapeutics Inc. (DNTH) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD

Target Add to Watchlist

Take a Tour

Strong Buy

Average Analyst
Rating

Very Bullish

Stock Target Advisor
Analysis

N/A

Average User
Rating

Last Closing Price

USD 26.35

Change

-1.33 (-4.80)%

Market Cap

N/A

Volume

0.24M

Avg User Target

N/A

DNTH

Dianthus Therapeutics Inc. (USD)

COMMON STOCK | NSD

USD 26.35

-1.33 ( -4.80)%

Watchlist

ETFs Holding Dianthus Therapeutics Inc. (DNTH)

Exchange

Symbol	Name	Exchange	DNTH's Weight	Expense Ratio	Price(Change)	Market Cap
no data

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.